Evidence map›Paper›PMID 42164472›Full record

ArticleBioinformatics and biology insights2026

Computational Characterization of Nabilone-Induced Disruption of the CB2-HER2 Receptor Complex in HER2+ Breast Cancer.

Abbou Hanane, Zegrari Razana, Gaouzi Zainab, Festali Rihab, Chemao-Elfihri Mohammed Walid, Hakmi Mohammed, El Jaoudi Rachid

Abstract read
In one paragraph

Article in Bioinformatics and biology insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abbou HananeLaboratory of Drug Sciences (LRSM), Mohammed VI Faculty of Medicine Casablanca, Mohammed VI University of Sciences and Health (UM6SS), Morocco.ORCID https://orcid.org/0009-0002-1793-4638
Zegrari RazanaLaboratory of Drug Sciences (LRSM), Mohammed VI Faculty of Medicine Casablanca, Mohammed VI University of Sciences and Health (UM6SS), Morocco.
Gaouzi ZainabMohammed VI Center for Research and Innovation (CM6RI), Rabat, Morocco.ORCID https://orcid.org/0009-0008-9167-5228
Festali RihabMohammed VI Center for Research and Innovation (CM6RI), Rabat, Morocco.
Chemao-Elfihri Mohammed WalidMohammed VI Center for Research and Innovation (CM6RI), Rabat, Morocco.ORCID https://orcid.org/0000-0002-8624-5839
Hakmi MohammedMohammed VI Center for Research and Innovation (CM6RI), Rabat, Morocco.
El Jaoudi RachidMohammed VI Center for Research and Innovation (CM6RI), Rabat, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer, accounting for 15% to 20% of cases, is often resistant to treatment. Delta-9-tetrahydrocannabinol (THC) disrupts HER2-cannabinoid receptor (2CB2) receptor complexes and inhibits HER2 activation. This study evaluates whether Nabilone, a synthetic cannabinoid, can similarly disrupt HER2-CB2 interactions. A CB2-HER2 complex model was generated via protein-protein docking. Three 1-µs molecular dynamics simulations (CB2-HER2, CB2-HER2-THC, CB2-HER2-Nabilone) were performed using the Schrodinger Desmond with membrane embedding and solvent. Structural stability (root mean square deviation [RMSD] and root mean square fluctuation [RMSF]), binding free energy (molecular mechanics/generalized born surface area [MM/GBSA]), and intracellular/extracellular distances between receptors were analyzed. Intermolecular interactions were assessed using the MAPIYA server. Nabilone induced comparable structural instability to THC, with increased RMSD and RMSF. The MM/GBSA analysis showed Nabilone increased the binding free energy between CB2 and HER2, indicating stronger disruption. Intracellular and extracellular distances between CB2 and HER2 increased, especially intracellularly, with Nabilone. Intermolecular interaction analysis revealed that Nabilone decreased the number of contacts, particularly hydrophobic interactions, between CB2 and HER2. Our in silico model predicts that Nabilone may disrupt the HER2-CB2 complex, suggesting a hypothesis that it could serve as a potential therapeutic agent. These computational findings warrant urgent experimental validation.

Indexed as

cannabinoidCB2 receptorHER2+ breast cancerMD simulationmolecular modelingnabilone

Identifiers

PMID42164472
PMCPMC13184371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.